In addition to the trio of filings, one biotech IPO closed last week, as San Diego-based Ambit Biosciences Corp...A week earlier, Receptos Inc., also of San Diego, priced its IPO, raising $72.8 million by selling 5.2 million shares at $14 apiece

Phase I/II data reported by San Diego-based TargeGen prior to the Sanofi buyout also showed the potential of SAR302503 to reduce white blood cell count in patients with leukocytosis and reduce mutant cells responsible for causing the disease in about two-thirds of the patients treated

AnaptysBio Inc., of San Diego, disclosed a contract award from the U.S

The San Diego-based biotech priced about 8.1 million shares at $8 apiece for gross proceeds of about $65 million

Acadia Pharmaceuticals Inc., of San Diego, priced a $100 million public offering of 8 million shares of common stock at $12.50 apiece, a 3.5 percent discount to Tuesday's closing price...Receptos Inc., of San Diego, said it completed its initial public offering of 5.2 million shares priced at $14 apiece for proceeds of $72.8 million and granted underwriters Credit Suisse Securities LLC, Leerink Swann LLC, BMO Capital Markets and Wedbush PacGrow Life Sciences a 30-day option to purchase up to an

and Cytori Therapeutics Inc., of San Diego.

On completion of the transaction, which is due to happen Wednesday, Cosmo will retain almost 3 million Santarus shares, representing 4.63 percent of the San Diego-based firm's stock

Sorrento Therapeutics Inc., of San Diego, and Igdrasol Inc., of Irvine, Calif., said they acquired exclusive distribution rights from Samyang Biopharmaceuticals, a South Korean firm, to Cynviloq (marketed as Genexol-PM in South Korea) in the 27 countries of the European Union

On completion of the transaction, which is due to happen Wednesday, Cosmo will retain almost 3 million Santarus shares, representing 4.63 percent of the San Diego-based firm's stock

Prometheus Laboratories Inc., of San Diego, said PROCLIVITY 01, a multicenter study of Proleukin (High Dose Interleukin-2 [HD IL-2])1 plus vemurafenib therapy in patients with BRAF V600 mutation-positive metastatic melanoma (mM) is enrolling patients

MediciNova Inc., of San Diego, entered a securities purchase agreement, selling about 1.2 million shares of common stock priced at $3.15 apiece

San Diego) PEGPH20 A pegylated form of rHuPH20 Stage IV metastatic pancreatic cancer Started a Phase II trial 4/24/13 Merrimack Pharmaceuticals Inc. (Cambridge, Mass.) MM-121 A signaling inhibitor targeting ErbB3 HER2-negative breast cancer The final patient was enrolled in one group of a two-cohort Phase II trial of MM-121 combined with paclitaxel 4/16/13 Merrimack Pharmaceuticals Inc. (Cambridge, Mass.) MM-121 A signaling inhibitor targeting ErbB3 Non-small-cell lung cancer One cohort of a

San Diego) TR-701 Tedizolid phosphate Linezolid-resistant strain of bacteria Data demonstrated it did not increase blood pressure when used in conjunction with vasoconstrictor drugs such as decongestants 4/30/13 Notes: Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue

Company (Location) Product Description Indication Status Date AUTOIMMUNE Acorda Therapeutics Inc. (Ardsley, N.Y.) rHIgM22 A remyelinating antibody Multiple sclerosis Enrollment began in the first trial 4/24/13 Arena Pharmaceuticals Inc. (San Diego) APD334 An oral drug targeting the sphingosine 1-phosphate subtype 1 receptor Autoimmune diseases Initiated dosing in a Phase I trial 4/8/13 Idera Pharmaceuticals Inc. (Cambridge, Mass.) IMO-8400 An agonist of Toll-like receptors 7, 8 and 9 Psoriasis

San Diego) Etarfolatide Molecular imaging agent Osteoarthritis Data showed it may identify and differentiate inflammatory from non-inflammatory diseases states 4/29/13 MISCELLANEOUS BHR Pharma LLC (Herndon, Va.) BHR-100 Intravenous progesterone infusion agent Severe traumatic brain injury The 1,000th patient was enrolled in the global Phase III study 4/16/13 EyeGate Pharma Inc. (Waltham, Mass.) EGP-437 Comprises a formulation of dexamethasone delivered into the eye using an ocular iontophoresis

San Diego) and Eisai Inc. (Woodcliff Lake, N.J.) Belviq Lorcaserin HCl Chronic weight management Submitted an MAA for its use as an adjunct to a reduced-calorie diet and increased physical activity 4/2/13 Avanir Pharmaceuticals Inc. (Aliso Viejo, Calif.) Nuedexta Dextrometh-orphan hydrobromide and quinidine sulfate Pseudobulbar affect CHMP recommended approval 4/29/13 Trigemina Inc. (Moraga, Calif.) TI-001 Intranasal oxytocin Chronic migraine Chile approved the protocol for a Phase II study 4/10

plc (Bedminster, N.J., and Dublin, Ireland) Vascepa Icosapent ethyl capsules High triglycerides FDA accepted its supplemental NDA for use as an adjunct to diet 4/24/13 Santarus Inc. (San Diego) and Pharming Group (Leiden, the Netherlands) Ruconest Recombinant human C1 esterase inhibitor Hereditary angioedema Submitted a BLA 4/18/13 CENTRAL NERVOUS SYSTEM Acadia Pharmaceuticals Inc. (San Diego) Pimaanserin Oral tablet Parkinson's disease psychosis FDA said the company will not need another Phase

Receptos Inc., of San Diego, priced its initial public offering (IPO) of 5.2 million shares of common stock at $14 per share, for a total raise of $72.8 million